Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

NCT00063934 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

31

Enrollment

NIH

Sponsor class

Conditions

Male Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions

BIOLOGICAL: oblimersen sodium
DRUG: doxorubicin hydrochloride
DRUG: docetaxel
BIOLOGICAL: filgrastim
BIOLOGICAL: pegfilgrastim
PROCEDURE: therapeutic conventional surgery
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)